首页|河南省食管癌新辅助免疫治疗诊疗路径

河南省食管癌新辅助免疫治疗诊疗路径

扫码查看
食管癌是河南区域高发肿瘤,给家庭和社会带来沉重医疗负担.手术治疗在非晚期食管癌治疗中占主导地位,但食管癌病灶内癌细胞具有较强的浸润性,术后复发率和转移率均很高,亟需更为有效的全身综合治疗来改善预后.我们组织32家河南省各级医院,52位食管外科、肿瘤科、病理科、影像科及放疗科医师,结合国内外循证医学证据及临床实践经验,反复磋商和充分讨论,制定《河南省食管癌新辅助免疫治疗诊疗路径》,从目标人群、患者评估、方案选择、手术时机、术后管理、器官保留、总则等7个角度提出了 7条推荐意见,供食管癌外科相关医务人员参考使用.
Diagnosis and treatment pathway of neoadjuvant immunotherapy for esophageal cancer in Henan province
Esophageal cancer is a highly prevalent tumor species in Henan province,which brings heavy medical burden to families and society.Surgical treatment plays a dominant role in the treatment of non-advanced esophageal cancer.However,cancer cells in esophageal cancer lesions are highly invasive,postoperative recurrence and metastasis rates are pretty high.More effective systemic and comprehensive treatment is urgently needed to improve the prognosis.We invited 52 doctors in esophageal surgery,oncology,pathology,imaging,and radiation therapy of 32 hospitals at all levels in Henan province,to repeatedly negotiate and fully discuss in combination with evidence and clinical practice experience.Finally,"diagnosis and treatment pathway of neoadjuvant immunotherapy for esophageal cancer in Henan province"was formulated.In this treatment pathway,seven recommendations were proposed from seven perspectives including target population,patient evaluation,protocol selection,surgical timing,postoperative management,organ preservation,and general principles to offer reference for medical personnel related to esophageal cancer surgery.

Esophageal cancerneoadjuvantimmunotherapydiagnosis and treatment pathway

魏立、邢文群、杨洋、代表《河南省食管癌新辅助免疫治疗诊疗路径》编写组

展开 >

河南省人民医院胸外科(郑州 450003)

河南省肿瘤医院胸外科(郑州 450003)

郑州大学第一附属医院胸外科(郑州 450052)

食管癌 新辅助 免疫治疗 诊疗路径

2024

中国胸心血管外科临床杂志
四川大学华西医院

中国胸心血管外科临床杂志

CSTPCD北大核心
影响因子:0.846
ISSN:1007-4848
年,卷(期):2024.31(2)
  • 6